There’s a new FDA-approved dry eye treatment on the scene. On Tuesday, the U.S. regulators green-lighted Kala Pharmaceuticals’ (KALA) EYSUVIS 0.25% for the treatment of signs and symptoms of dry eye disease (DED).The go ahead from the FDA makes EYSUVIS the first and only approved corticosteroid for this indication and comes several days ahead of the scheduled October 30 PDUFA. Wedbush analyst Liana Moussatos believes this reflects “both the strength of the regulatory data package” and the “unmet need in this patient population that suffers from a lack of rapid and adequate relief from dry eye flares.”With a plan to …read more
Source:: Yahoo Finance
